Endo Buys Dava, Building In Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
The acquisitive specialty pharma will buy privately-held generics firm Dava Pharmaceuticals for $575 million in cash and potentially another $25 million based on the achievement of certain sales milestones.